Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nuvectis Pharma, Inc. (NVCT) had Return on Tangible Equity of -195.61% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-19.00M |
|
-- |
|
-- |
|
$19.85M |
|
$-19.85M |
|
$0.85M |
|
$-19.00M |
|
$-19.00M |
|
$-19.00M |
|
$-19.00M |
|
$-19.00M |
|
$-19.00M |
|
$-19.85M |
|
$-19.85M |
|
17.11M |
|
17.11M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$18.61M |
|
-- |
|
-- |
|
$18.61M |
|
$8.89M |
|
-- |
|
-- |
|
$8.89M |
|
$9.71M |
|
$9.71M |
|
$9.71M |
|
19.50M |
|
| Cash Flow Statement Financials | |
$-12.25M |
|
-- |
|
$11.65M |
|
$19.13M |
|
$18.53M |
|
$-0.59M |
|
$4.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-195.61% |
|
|
Return on Tangible Equity |
-195.61% |
-102.11% |
|
-195.61% |
|
$0.50 |
|
$-0.72 |
|
$-0.72 |
|